Miami, FL Clinical Trials Report — June 2026

For Miami residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, with a significant number of trials nearing their enrollment deadlines. Across Miami, FL, 1,310 clinical trials are currently recruiting across 849 research facilities, offering diverse avenues for contributing to medical advancements.

A total of 80 trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (4 trials)
• Major depressive disorder (3 trials)
• Venous leg ulcer (2 trials)
• Lung cancer (2 trials)
• Type 2 diabetes (2 trials)
• Vulvovaginal candidiasis (VVC) (2 trials)
• Cancer (2 trials)
• COPD (2 trials)
• Diabetes mellitus, type 2 (2 trials)
• Diabetic foot ulcer (DFU) (2 trials)

New Research Opportunities Emerge in Miami

This month, Miami saw the opening of 24 new clinical trials, a slight decrease from the 30 trials that launched in May 2026. These new studies bring fresh opportunities for participation across a range of conditions and research types.

June brings several high-profile new trials to Miami, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 randomized, double-blind, placebo-controlled study involving 1,100 participants. It will evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus.
• Pfizer is sponsoring NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This Phase 3 study aims for 3,230 participants to learn about the safety and effectiveness of a new pneumococcal vaccine in infants compared to existing vaccines.
• Novo Nordisk A/S is leading NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This Phase 3 study with 650 participants seeks to determine if zenagamtide is safe and effective for treating participants with excess body weight compared to semaglutide.
• Tonix Pharmaceuticals, Inc. is sponsoring NCT07621237, "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)." This Phase 2 trial aims for 360 participants to learn if TNX-102 SL works to treat moderate to severe major depressive disorder in adults and to assess its safety.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," a long-term study involving 1,400 participants. The goal is to better understand the health, development, and everyday experiences of people with Down syndrome of all ages over time.

New trials this month are exploring a range of conditions, with the most frequent being obesity (4 trials), overweight (4 trials), chronic weight management (2 trials), and chronic pain (2 trials). Drug trials account for the largest share of new studies, with 15 new drug trials, followed by 6 other types of studies and 4 behavioral studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 5 of the 24 new trials launched this month are actively seeking healthy volunteers. Across Miami, a total of 114 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Miami's Leading Research Facilities

Miami is home to some of Florida's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Miami (232 trials)
• University of Miami Miller School of Medicine-Sylvester Cancer Center (82 trials)
• Nicklaus Children's Hospital (58 trials)
• Miami Cancer Institute (51 trials)
• UM Sylvester Comprehensive Cancer Center at Kendall (34 trials)
• Research Site (32 trials)
• Sylvester Comprehensive Cancer Center (28 trials)
• GSK Investigational Site (18 trials)
• University of Miami Hospital (17 trials)
• University of Miami Miller School of Medicine (17 trials)
• Miami Cancer Institute at Baptist Health, Inc. (16 trials)
• Bascom Palmer Eye Institute (15 trials)

These institutions offer a broad spectrum of research, from oncology at the various Sylvester Cancer Centers and Miami Cancer Institute, to pediatric care at Nicklaus Children's Hospital, and diverse medical fields at the University of Miami and its associated facilities.

Broadening Your Search: Nearby Options in Florida

While Miami offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Jacksonville (17 trials), Orlando (16 trials), Tampa (13 trials), Maitland (8 trials), Ocala (7 trials), Leesburg (6 trials), Ocoee (5 trials), and Hollywood (5 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 24 new trials launched this month, 18 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, 2 are female-only, and 2 are male-only. Academic institutions continue to play a vital role in Miami's research ecosystem, with the University of Miami sponsoring 5 new studies. Industry sponsors like Gasherbrum Bio, Inc. (2 trials), Eli Lilly and Company (2 trials), and Novo Nordisk A/S (1 trial) are also driving significant research efforts, with 17 new industry-sponsored trials this month.

As we move through June, Miami's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and improve health outcomes for many.